Search

Displaying results 9361 - 9370 of 9617 in total
  1. Drug

    Bavtavirine

    go.drugbank.com/drugs/DB21527
    Investigational

    Bavtavirine has a monoisotopic molecular weight of 416.17 Da.

  2. Drug

    Wortmannin

    go.drugbank.com/drugs/DB08059
    Experimental

    This drug acts as a nonspecific, covalent inhibitor of phosphoinositide 3-kinase enzymes (PI3Ks).

  3. Drug

    Buntanetap

    go.drugbank.com/drugs/DB15317
    Investigational

    Buntanetap (previously known as Posiphen) is under investigation in clinical trial NCT02925650 (Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease).

  4. Drug

    D-1,4-dithiothreitol

    go.drugbank.com/drugs/DB02184
    Experimental

    A reagent commonly used in biochemical studies as a protective agent to prevent the oxidation of SH (thiol) groups and for reducing disulphides to dithiols. [PubChem]

  5. Drug

    Darapladib

    go.drugbank.com/drugs/DB06311
    Investigational

  6. Drug

    Amniotic Epithelial Cells

    go.drugbank.com/drugs/DB15868
    Investigational

    Amniotic epithelial cells (AEC) are multipotent stem-like cells derived from the basement collagenous membrane of the human amnion, the layer of the placenta closest to the fetus. These cells are potential candidates for allogeneic cell ...

  7. Drug

    Imidocarb

    go.drugbank.com/drugs/DB11521
    ExperimentalVet approved

    Imidocarb is a urea derivative used in veterinary medicine as an antiprotozoal agent for the treatment of infection with Babesia and other parasites.

  8. Drug

    Plixorafenib

    go.drugbank.com/drugs/DB16038
    Investigational

    PLX8394 is under investigation in clinical trial NCT02428712 (A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors).

  9. Drug

    Pelitinib

    go.drugbank.com/drugs/DB05524
    Investigational

    Pelitinib (EKB-569) is a potent, low molecular weight, selective, and irreversible inhibitor of epidermal growth factor receptor (EGFR) that is being developed as an anticancer agent.

  10. Drug

    CTT-1057

    go.drugbank.com/drugs/DB14965
    Investigational

    CTT-1057 is under investigation in clinical trial NCT03427476 (CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma).